Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients.
Both alprazolam and diazepam were superior to placebo for the treatment of the clinical anxiety syndrome throughout a four-week double-blind multiclinic trial in 976 outpatients. At the fourth-week evaluation of the 845 patients completing the study, the 326 patients receiving alprazolam showed significantly more improvement than the 344 patients receiving diazepam on all 4 anxiety rating scales utilized (Hamilton Anxiety Rating Scale, Physician's Global Assessment, Patient's Global Assessment, and Target Symptoms).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000525:Alprazolam; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors
D014151:Anti-Anxiety Agents; D010919:Placebos; D001569:Benzodiazepines; D003975:Diazepam; D000525:Alprazolam